Power3 Medical Products, Inc. (OTC:PWRM)
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM's products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease. PWRM's products analyze proteins and their mutations to assess an individual's risk for developing disease later in life or a patient's likelihood of responding to a particular drug; assess a patient's risk of disease progression and disease recurrence; and measure a patient's exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
PWRM, a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced earlier this month that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM's diagnostic test, and focused on PWRM's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, PWRM's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."
"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of PWRM, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."
"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.
To learn more about PWRM visit: http://www.Power3Medical.com
Palatin Technologies, Inc. (Amex:PTN)
PTN, a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, recently announced results for its fourth quarter and fiscal year ended June 30, 2010. All share and per share amounts are presented on a post-reverse-split basis, giving effect to the 1-for-10 reverse stock split announced on September 24, 2010.
PTN's net loss for the year ended June 30, 2010 was $1.8 million, or $(0.18) per basic and diluted share, compared to a net loss of $4.8 million, or $(0.56) per basic and diluted share, for the year ended June 30, 2009.
PTN, a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (NYSE:MC) and natriuretic peptide receptor systems in the United States. PTN was founded in 1986 and is based in Cranbury, New Jersey.
To learn more about PTN visit: http://www.palatin.com
Paramount Gold & Silver Corporation (Amex:PZG)
PZG announced recently a $3 million exploration program designed to expand and upgrade resources at our 100% owned Sleeper Gold Mine Project in Nevada. PZG is also commencing a study to determine the feasibility for near-term exploitation of the property`s large surface mineral inventory of gold in tailings and heaps. The Sleeper Project was acquired in the recently completed takeover of X-Cal Resources.
PZG engages in the acquisition, exploration, and development of gold, silver, and precious metal properties primarily in Mexico, as well as in British Columbia, Canada. PZG primarily explores and develops the San Miguel Project located in the State of Chihuahua, Mexico. PZG was formerly known as Paramount Gold Mining Corp. and changed its name to Paramount Gold and Silver Corp. in August 2007. PZG was founded in 2005 and is based in Ottawa, Canada.
To learn more about PZG visit: http://www.paramountgold.com
Pernix Therapeutics Holdings, Inc. (Amex:PTX)
PTX, a specialty pharmaceutical company primarily focused on the pediatric market, recently announced the acquisition of 100% of the outstanding membership interest in Macoven Pharmaceuticals, L.L.C. (“Macoven”) for approximately $2.2 million (which includes inventory of approximately $1.2 million), its entry into a $10 million credit facility with Regions Bank (“Regions”) and the repurchase of 2,000,000 shares of its common stock from one of its employees in a privately negotiated transaction.
PTX, a specialty pharmaceutical company, engages in the acquisition, development, marketing, and distribution of branded pharmaceutical products to meet unmet medical needs, primarily in pediatrics. PTX sells its products directly to drug wholesalers, who in turn distribute the products to retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. PTX was founded in 1999 and is based in Houston, Texas.
To learn more about PTX visit: http://www.pernixtx.com
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (OTC:PWRM). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (OTC:PWRM). Each advertising commitment has now expired.